^
    Back
    Association details:
    Biomarker:CDKN2A mutation
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO-GU 2021
    Title:

    CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).

    Published date:
    02/08/2021
    Excerpt:
    CDKN2A alterations were significantly associated with shorter OS and TTF in the DFCI UC and melanoma cohorts by MVA, and showed a trend towards significance in the MSKCC UC cohort (Table).
    DOI:
    10.1200/JCO.2021.39.6_suppl.475